Powerful Prophylaxis
Your Journey, Without Interruptions
Attack reduction with ANDEMBRY means making decisions about your own future, with less compromises related to HAE management.
Photo does not depict actual patient
ANDEMBRY Provides Significant Reduction in HAE Attacks
A median reduction of >99% was calculated because at least half of the ANDEMBRY-treated patients experienced a complete reduction in monthly HAE attack rates compared to placebo. Patients receiving ANDEMBRY in the clinical trial experienced an adjusted average of 89% (LS; least squares) reduction in monthly HAE attack rate compared to placebo.
* With all HAE medications, attacks can still occur. Patients should always have a rescue medication.
† At 6 months.
LS, least squares
ANDEMBRY, THE FIRST AND ONLY ONCE-MONTHLY HAE PROPHYLAXIS TREATMENT FROM THE START FOR ALL PATIENTS
- Monthly dosing from the start for all patients 12 years and older
- Subcutaneous self-injection delivered in ≤15 seconds via a convenient autoinjector
- No reports of injection-site pain§
§ In the VANGUARD pivotal phase 3 trial. Patients in the pivotal study and open-label extension study experienced injection-site redness, itching, and bruising.
Innovation in Action
Only ANDEMBRY, a monoclonal antibody, inhibits FXIIa at the top of the HAE pathway
Innovation in Action
Only ANDEMBRY, a monoclonal antibody, inhibits FXIIa at the top of the HAE pathway